PDCD1 and endometrial cancer: Among the patients with endometrial cancer, the estimated PFS rate was significantly in favor of the PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel chemotherapy-based group (HR 0.52; 95% CI 0.34–0.80; p < 0.01; I2=80%; Fig. 2).